Last reviewed · How we verify
NCT04391647: HPV-VACPLUS
Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples
trial testing First-void urine collection in Human Papilloma Virus Infection in 50 participants. Completed in 1 July 2020.
1 July 2020
Quick facts
| Lead sponsor | Universiteit Antwerpen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 11 May 2020 |
| Primary completion | 1 July 2020 |
| Estimated completion | 1 July 2020 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- First-void urine collection
- Blood draw — full drug profile →
Conditions studied
- Human Papilloma Virus Infection — all drugs for Human Papilloma Virus Infection →
Sponsor
Universiteit Antwerpen — full company profile →
Who can join
Adults 18 to 25, female only, with Human Papilloma Virus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this study is to develop protocols using FV urine that investigate in vitro whether infectious virions can be neutralized by HPV vaccination.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
HPV-specific antibodies in female genital tract secretions captured via first-void urine retain their neutralizing capacity.
Téblick L, Lipovac M, Molenberghs F, Delputte P, et al · · 2024 · cited 5× · PMID 38567541 · DOI 10.1080/21645515.2024.2330168
Verify or expand the search:
- PubMed search for NCT04391647
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of First-void urine collection
Trials testing the same drug.
- NCT03542227 — Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine · completed
Other recruiting trials for Human Papilloma Virus Infection
Currently open trials in the same condition.
- NCT06467942 — Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection · NA · recruiting
Other Universiteit Antwerpen trials
Trials by the same sponsor.
- NCT07407569 — Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After H · Phase 2 · recruiting
- NCT07355101 — Personalized Exercise Coaching to Improve Quality of Life in Pediatric IBD · NA · active not recruiting
- NCT06962579 — The Effect of Personalized Exercise Interventions for the Prevention of Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
- NCT06999473 — Assessment and Treat Neglect Patients With a VR Application · NA · not yet recruiting
- NCT07161531 — Test-retest Reliability of sEMG to Measure Fatigue in Adolescents · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04391647 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universiteit Antwerpen
- Last refreshed: 29 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04391647.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing